中国综合临床
中國綜閤臨床
중국종합림상
Clinical Medicine of China
2015年
10期
925-927
,共3页
左卡尼汀%蔗糖铁注射液%肾性贫血
左卡尼汀%蔗糖鐵註射液%腎性貧血
좌잡니정%자당철주사액%신성빈혈
Levocarnitine%Sucrose iron injection%Renal anemia
目的 观察左卡尼汀联合蔗糖铁注射液治疗维持性血液透析患者肾性贫血的临床效果.方法 选取维持性血液透析合并肾性贫血患者44例,随机分成对照组和治疗组,每组22例.所有患者均给予常规治疗,对照组于透析时给予蔗糖铁注射液,治疗组在此基础上,于透析结束后静脉注射左卡尼汀.治疗8周后检测血红蛋白(Hb)和红细胞比体积(Hct)并进行比较,对其临床疗效进行评估.结果 治疗8周后,两组Hb[治疗组(105.69±11.94) g/L、对照组(86.31±11.39) g/L]、Hct[治疗组0.31±0.04、对照组0.27±0.05]水平较治疗前Hb[治疗组(62.65±12.74) g/L、对照组(63.33±13.23)g/L]、Hct[治疗组(0.19±0.04)、对照组(0.20±0.06)]均明显升高,差异均有统计学意义(P均＜0.05);且治疗组[Hb(105.69±11.94) g/L、Hct(0.31±0.04)]较对照组[Hb(86.31±11.39) g/L、Hct(0.27±0.05)]升高效果更显著,差异均有统计学意义(t=3.197,t=2.978,P均＜0.05).治疗组的总有效率为86.4％(19/22),显著高于对照组的50.0％(11/22),差异有统计学意义(x2=6.705,P＜0.05).结论 左卡尼汀联合蔗糖铁注射液更明显地改善维持性血液透析患者的贫血症状.
目的 觀察左卡尼汀聯閤蔗糖鐵註射液治療維持性血液透析患者腎性貧血的臨床效果.方法 選取維持性血液透析閤併腎性貧血患者44例,隨機分成對照組和治療組,每組22例.所有患者均給予常規治療,對照組于透析時給予蔗糖鐵註射液,治療組在此基礎上,于透析結束後靜脈註射左卡尼汀.治療8週後檢測血紅蛋白(Hb)和紅細胞比體積(Hct)併進行比較,對其臨床療效進行評估.結果 治療8週後,兩組Hb[治療組(105.69±11.94) g/L、對照組(86.31±11.39) g/L]、Hct[治療組0.31±0.04、對照組0.27±0.05]水平較治療前Hb[治療組(62.65±12.74) g/L、對照組(63.33±13.23)g/L]、Hct[治療組(0.19±0.04)、對照組(0.20±0.06)]均明顯升高,差異均有統計學意義(P均＜0.05);且治療組[Hb(105.69±11.94) g/L、Hct(0.31±0.04)]較對照組[Hb(86.31±11.39) g/L、Hct(0.27±0.05)]升高效果更顯著,差異均有統計學意義(t=3.197,t=2.978,P均＜0.05).治療組的總有效率為86.4％(19/22),顯著高于對照組的50.0％(11/22),差異有統計學意義(x2=6.705,P＜0.05).結論 左卡尼汀聯閤蔗糖鐵註射液更明顯地改善維持性血液透析患者的貧血癥狀.
목적 관찰좌잡니정연합자당철주사액치료유지성혈액투석환자신성빈혈적림상효과.방법 선취유지성혈액투석합병신성빈혈환자44례,수궤분성대조조화치료조,매조22례.소유환자균급여상규치료,대조조우투석시급여자당철주사액,치료조재차기출상,우투석결속후정맥주사좌잡니정.치료8주후검측혈홍단백(Hb)화홍세포비체적(Hct)병진행비교,대기림상료효진행평고.결과 치료8주후,량조Hb[치료조(105.69±11.94) g/L、대조조(86.31±11.39) g/L]、Hct[치료조0.31±0.04、대조조0.27±0.05]수평교치료전Hb[치료조(62.65±12.74) g/L、대조조(63.33±13.23)g/L]、Hct[치료조(0.19±0.04)、대조조(0.20±0.06)]균명현승고,차이균유통계학의의(P균＜0.05);차치료조[Hb(105.69±11.94) g/L、Hct(0.31±0.04)]교대조조[Hb(86.31±11.39) g/L、Hct(0.27±0.05)]승고효과경현저,차이균유통계학의의(t=3.197,t=2.978,P균＜0.05).치료조적총유효솔위86.4％(19/22),현저고우대조조적50.0％(11/22),차이유통계학의의(x2=6.705,P＜0.05).결론 좌잡니정연합자당철주사액경명현지개선유지성혈액투석환자적빈혈증상.
Objective To observe the clinical effects of levocarnitine combined with sucrose iron injection for treatment of maintenance hemodialysis patients with renal anemia.Methods Forty-four cases of patients with maintenance hemodialysis merged renal anemia were randomly divided into control group (n =22) and treatment group(n=22).All patients were administrated conventional therapy.The sucrose iron injection was administrated with control group at hemodialysis, while treatment group administrated levocamitine after hemodialysis on this basis.The hemoglobin (Hb) and erythrocyte specific volume (Hct) were compared after treatment for 8 weeks,and the clinical effects were evaluated.Results After treatment for 8 weeks, the Hb and Hct(treatment group: (105.69±11.94) g/L, (0.31±0.04);control group: (86.31±11.39) g/L,0.27±0.05) had increased significantly compared with prior treatment(treatment group:(62.65± 12.74) g/L, (0.19±0.04;control group: (63.33 ± 13.23) g/L, 0.20± 0.06) in two groups, and the treatment group increased more significant than control group accompanied with significant statistically difference (t =3.197,2.978;P ＜0.05).Also,the total effective rate of treatment group was 86.4％(19/22) ,which higher than control group(50.0％ (11/22)) accompanied with significant statistically difference (x2 =6.705, P＜0.05).Conclusion The therapy of levocarnitine combined with sucrose iron injection can obviously improve anemia symptoms in patients with maintenance hemodialysis and worthy of popularization and application.
